Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic liver disease and type 2 diabetes
Patients with CTP B cirrhosis and T2DM receiving SGLT2i therapy experienced a significant improvement in renal, hepatic function, and glycemic control over 48 months compared to patients treated with insulin.
Authors
- Deepika Devuni (ORCID: https://orcid.org/0000-0002-1011-9414)
- Alessandro Colletta (ORCID: https://orcid.org/0000-0002-3865-1015)
- Katherine M. Cooper (ORCID: https://orcid.org/0000-0002-6030-4773)
- C. Colletta (ORCID: https://orcid.org/0000-0002-5910-3253)
- Giuseppe Placentino
Institutions
- UMass Memorial Health Care (US)
- Madonna Rehabilitation Hospital (US)
- University of Massachusetts Chan Medical School (US)
- Azienda Sanitaria Locale Roma 3 (IT)
- UMass Memorial Medical Center (US)
Publication Details
- Journal
- Frontiers in Endocrinology
- Published
- 2025-05-15
- DOI
- https://doi.org/10.3389/fendo.2025.1531295
- Citations
- 3
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 4.06